Stay updated on Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial

Sign up to get notified when there's something new on the Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Revision: v3.4.3 was added, and Revision: v3.4.2 was removed from the page.
    Difference
    0.1%
    Check dated 2026-03-12T00:40:49.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added. The government funding status notice and Revision: v3.4.1 were removed.
    Difference
    0.4%
    Check dated 2026-02-11T12:30:59.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Added a government funding lapse notice and Clinical Center status guidance, and updated the site revision to v3.4.1 (replacing v3.4.0); to avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T06:43:12.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Glossary display has been added, and the label 'Last Update Submitted that Met QC Criteria' appears with updated capitalization. Footer text now shows 'No FEAR Act data' and 'Revision: v3.4.0', replacing the previous wording and version.
    Difference
    0.2%
    Check dated 2026-01-28T04:33:00.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Minor revision label updated from v3.3.3 to v3.3.4; no changes to study details, eligibility criteria, or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T01:49:07.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    A new consolidated Locations section lists participating sites by state (Florida, Missouri, Oklahoma, Tennessee, Texas, Wisconsin) and the prior state-specific location subsections have been removed.
    Difference
    0.7%
    Check dated 2025-12-23T17:27:02.000Z thumbnail image

Stay in the know with updates to Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial page.